Sam Brusco, Associate Editor06.25.24
DuPont has begun a deal to acquire Donatelle Plastics, a medical device contract manufacturer that specializes in design, development, and manufacture of medical components and devices.
DuPont’s healthcare exposure includes Spectrum Plastics, a developer of medical device components, and Liveo, a developer of silicone solutions for healthcare applications. Acquiring Donatelle brings the complementary tech and capabilities of medical device injection molding, liquid silicone rubber (LSR) processing, precision machining, device assembly, and tool building.
Donatelle’s therapeutic areas include electrophysiology, drug delivery, diagnostics, cardiac rhythm management, neurostimulation, and orthopedic extremities. The company has a workforce of over 400 employees and runs a facility located in a medical technologies hub near large original equipment manufacturers.
"Our healthcare strategy is focused on offering a comprehensive suite of solutions for customers in high-growth therapeutic areas," said Jon Kemp, president, DuPont Electronics & Industrial (E&I). "Donatelle Plastics Incorporated will be the second acquisition, following Spectrum last year, that will deepen our expertise in the medical device market segments and enhance our position as a partner of choice for our customers."
The transaction is expected to close in Q3 2024.
"We're excited for this next chapter in Donatelle's journey and for our team of highly talented and skilled employees to join DuPont," added Treasa Springett, president of Donatelle Plastics Incorporated. "As a part of a broader healthcare offering, we will have even greater impact on patient outcomes by enabling the innovation and development of next generation devices for patients worldwide."
DuPont’s healthcare exposure includes Spectrum Plastics, a developer of medical device components, and Liveo, a developer of silicone solutions for healthcare applications. Acquiring Donatelle brings the complementary tech and capabilities of medical device injection molding, liquid silicone rubber (LSR) processing, precision machining, device assembly, and tool building.
Donatelle’s therapeutic areas include electrophysiology, drug delivery, diagnostics, cardiac rhythm management, neurostimulation, and orthopedic extremities. The company has a workforce of over 400 employees and runs a facility located in a medical technologies hub near large original equipment manufacturers.
"Our healthcare strategy is focused on offering a comprehensive suite of solutions for customers in high-growth therapeutic areas," said Jon Kemp, president, DuPont Electronics & Industrial (E&I). "Donatelle Plastics Incorporated will be the second acquisition, following Spectrum last year, that will deepen our expertise in the medical device market segments and enhance our position as a partner of choice for our customers."
The transaction is expected to close in Q3 2024.
"We're excited for this next chapter in Donatelle's journey and for our team of highly talented and skilled employees to join DuPont," added Treasa Springett, president of Donatelle Plastics Incorporated. "As a part of a broader healthcare offering, we will have even greater impact on patient outcomes by enabling the innovation and development of next generation devices for patients worldwide."